Boehringer Ingelheim discontinues work on NASH therapy candidate

Boehringer Ingelheim and Pharmaxis announced that development of BI 1467335 for the treatment of nonalcoholic steatohepatitis would be discontinued, according to a press release.“We are disappointed that BI 1467335 is not advancing in NASH,” Gary Phillips, CEO of Pharmaxis said in the release. “We look forward to further scientific discussion, when the full data and analysis from this phase 2a clinical trial and Boehringer Ingelheim’s recently reported phase I study are available for review.”Boehringer Ingelheim previously acquired BI 1467335 from Pharmaxis inRead More

Share on facebook
Share on twitter
Share on linkedin